{
    "pmcid": "10301551",
    "qa_pairs": {
        "What assays were used to validate the binding and functional activity of the nanobodies?": [
            "ELISA and plaque-forming assays",
            "Western blot and flow cytometry assays",
            "Mass spectrometry and immunoprecipitation assays",
            "Northern blot and qPCR assays"
        ],
        "What is the potential advantage of using neutralizing nanobodies like VH114 and VH278 as therapeutic agents?": [
            "They lack Fc regions, reducing the risk of antibody-dependent enhancement (ADE)",
            "They have longer half-lives compared to traditional monoclonal antibodies",
            "They can be administered orally, unlike traditional monoclonal antibodies",
            "They are less expensive to produce than traditional monoclonal antibodies"
        ],
        "What is the significance of identifying enhancing epitopes in the context of vaccine design?": [
            "To avoid these regions in subunit vaccines to prevent antibody-dependent enhancement (ADE)",
            "To incorporate these regions in vaccines to boost immune response",
            "To use these regions as primary targets for monoclonal antibody therapies",
            "To enhance the stability of vaccine formulations"
        ],
        "What technology was used to generate nanobodies against the SARS-CoV-2 RBD, and what was used as bait?": [
            "Phage display technology with a recombinant Wuhan RBD as bait",
            "CRISPR-Cas9 technology with a recombinant Delta RBD as bait",
            "Yeast display technology with a recombinant Omicron RBD as bait",
            "Bacterial display technology with a native spike protein as bait"
        ],
        "Which nanobodies were identified as neutralizing, and what variants did they bind to?": [
            "VH114 and VH278; they bound to recombinant Delta and Omicron RBDs and native spike proteins",
            "VH103 and VH105; they bound to recombinant Alpha and Beta RBDs and native spike proteins",
            "VH114 and VH105; they bound to recombinant Gamma and Lambda RBDs and native spike proteins",
            "VH278 and VH103; they bound to recombinant Mu and Epsilon RBDs and native spike proteins"
        ]
    }
}